Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level

Area of Science:

• Biophysics
• Spectroscopy
• Oncology

Background:

• Traditional in vitro drug efficacy monitoring focuses on single proteins, potentially misaligning with integral cell response and patient outcomes.
• Non-small cell lung cancer (NSCLC) patients with EGFR mutations often develop acquired resistance to tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

• To present a Raman spectroscopic method for detecting integral cell response to TKIs in NSCLC.
• To evaluate the method's ability to identify drug resistance associated with specific EGFR mutations.

Main Methods:

• Utilized Raman micro-spectroscopy to analyze the integral cellular response of NSCLC cells to TKIs.
• Investigated differences in spectral responses related to EGFR mutations (T790M, T790M/C797S) and TKI treatments (erlotinib, neratinib, osimertinib).

Main Results:

• Raman spectroscopy detected significant differences in NSCLC cells without the T790M EGFR mutation when treated with erlotinib.
• The method identified resistance to erlotinib in cells with T790M mutation and to osimertinib in cells with T790M/C797S mutation, aligning with clinical observations.
• Raman spectra also reflected cellular responses to neratinib and osimertinib in cells harboring specific EGFR mutations.

Conclusions:

• Raman micro-spectroscopy can effectively monitor drug resistance in NSCLC cells with specific EGFR mutations.
• This technique shows promise for in vitro companion diagnostics to guide personalized TKI therapies for cancer patients.